Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mustang Bio Inc.

Division of Fortress Biotech Inc.
www.mustangbio.com/

Latest From Mustang Bio Inc.

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma

Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.

Companies Deals

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property

Immuno-Oncology: Execs Talk About Tumor Response, Biomarkers, Lessons Learned

Leaders from Novartis and other companies developing cellular gene therapies share insights they've gleaned on manufacturing, clinical trials, and value-based pricing.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Mustang Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Fortress Biotech Inc.
  • Senior Management
  • Manuel Litchman, MD, Pres. & CEO
    Brian Achenbach, VP, Finance & Corp. Controller
    Sadik Kassim, PhD, CSO
    Knut Niss, PhD, CTO
    Martina A Sersch, MD, PhD, CMO
  • Contact Info
  • Mustang Bio Inc.
    Phone: (781) 652-4500
    2 Gansevoort St.
    9th Fl.
    New York, NY 10014
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register